Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Research Support, Non-U.S. Gov't

Review

Clinical Trial

Comparative Study

Randomized Controlled Trial

Multicenter Study

Clinical Trial, Phase III

Clinical Trial, Phase II

Case Reports

Research Support, N.I.H., Extramural

Systematic Review

Evaluation Study

Publication Year

From

Quick links

Individual year

2020

2019

2018

2017

2016

2015

2014

2010

2009

2008

2006

2004

2003

2002

2001

2000

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Anemia, Refractory""[mesh_terms]

21 Results

Searching titles within these results

Preliminary results of amifostine administration in combination with recombinant human erythropoietin in patients with myelodysplastic syndromes.

K L Bourantas, L Christou, K Panteli, H D Kapsali, S N Tsiara

Journal of experimental & clinical cancer research : CR 2001;20(1):35-8

Full Text

Abstract

Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.

Mrinal M Patnaik, Ayalew Tefferi

American journal of hematology 2017;92(3):297-310

Free Full Text

Abstract

Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".

Mrinal M Patnaik, Ayalew Tefferi

American journal of hematology 2019;94(4):475-488

Free Full Text

Abstract

Effect of intravenous ascorbic acid in hemodialysis patients with anemia and hyperferritinemia.

Keyhanian Shahrbanoo, Omolbanin Taziki

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 2009;19(6):933-6

Full Text

Abstract

Multicentre, open-label, randomised, parallel-group, superiority study to compare the efficacy of octreotide therapy 40 mg monthly versus standard of care in patients with refractory anaemia due to gastrointestinal bleeding from small bowel angiodysplasias: a protocol of the OCEAN trial.

J P H Drenth, K V Grooteman, E J M van Geenen

BMJ open 2017;6(9):e011442

Free Full Text

Abstract

DNA instability in low-risk myelodysplastic syndromes: refractory anemia with or without ring sideroblasts.

Bozena Novotna, Radana Neuwirtova, Magda Siskova, Yana Bagryantseva

Human molecular genetics 2008;17(14):2144-9

Full Text

Abstract

Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders.

Yisu Gu, Lise J Estcourt, Carolyn Doree, Sally Hopewell, Paresh Vyas

The Cochrane database of systematic reviews 2016;2015(10):CD011577

Free Full Text

Abstract

Bevacizumab for treating Hereditary Hemorrhagic Telangiectasia patients with severe hepatic involvement or refractory anemia.

Carolina Vázquez, María Laura Gonzalez, Augusto Ferraris, Juan Carlos Bandi, Marcelo Martín Serra

PloS one 2020;15(2):e0228486

Free Full Text

Abstract

Total iron-binding capacity and serum transferrin determination under the influence of several clinical conditions.

R Wigand, R Gottschalk, J P Kaltwasser, D Hoelzer, F Liebisch, C F Dietrich, G Oremek

Clinica chimica acta; international journal of clinical chemistry 2000;293(1-2):127-38

Full Text

Abstract

Erythropoietin administration may potentiate mobilization of storage iron in patients on oral iron chelation therapy.

Jaroslav Cermák

Hemoglobin 2006;30(1):105-12

Full Text

Abstract

Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts.

V Ribrag, F Suzan, C Ravoet, W Feremans, A Guerci, F Dreyfus, G Damaj, J M Vantelon, J H Bourhis, P Fenaux

Leukemia 2003;17(2):319-22

Full Text

Abstract

A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome.

Guillermo Garcia-Manero, Gary Gartenberg, David P Steensma, Martin R Schipperus, Dimitri A Breems, Raquel de Paz, David Valcárcel, Britte Kranenburg, Manjula Reddy, Rami S Komrokji

American journal of hematology 2014;89(9):E156-62

Free Full Text

Abstract

Refractory anemia with ring sideroblasts and RARS with thrombocytosis.

Mrinal M Patnaik, Ayalew Tefferi

American journal of hematology 2015;90(6):549-59

Free Full Text

Abstract

Refractory anemia with ring sideroblasts.

Luca Malcovati, Mario Cazzola

Best practice & research. Clinical haematology 2014;26(4):377-85

Full Text

Abstract

Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia.

R F Schlenk, S Fröhling, F Hartmann, J Th Fischer, A Glasmacher, F del Valle, W Grimminger, K Götze, C Waterhouse, R Schoch, H Pralle, H G Mergenthaler, M Hensel, E Koller, H Kirchen, J Preiss, H Salwender, H G Biedermann, S Kremers, F Griesinger, A Benner, B Addamo, K Döhner, R Haas, H Döhner

Leukemia 2004;18(11):1798-803

Full Text

Abstract

Results: 1 – 15 / 21

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Anemia, Refractory""[mesh_terms]

Preliminary results of amifostine administration in combination with recombinant human erythropoietin in patients with myelodysplastic syndromes.

Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.

Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".

Effect of intravenous ascorbic acid in hemodialysis patients with anemia and hyperferritinemia.

Multicentre, open-label, randomised, parallel-group, superiority study to compare the efficacy of octreotide therapy 40 mg monthly versus standard of care in patients with refractory anaemia due to gastrointestinal bleeding from small bowel angiodysplasias: a protocol of the OCEAN trial.

DNA instability in low-risk myelodysplastic syndromes: refractory anemia with or without ring sideroblasts.

Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders.

Bevacizumab for treating Hereditary Hemorrhagic Telangiectasia patients with severe hepatic involvement or refractory anemia.

Total iron-binding capacity and serum transferrin determination under the influence of several clinical conditions.

Erythropoietin administration may potentiate mobilization of storage iron in patients on oral iron chelation therapy.

Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts.

A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome.

Refractory anemia with ring sideroblasts and RARS with thrombocytosis.

Refractory anemia with ring sideroblasts.

Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia.

Results for
""Anemia, Refractory""[mesh_terms]